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ABSTRACT
Human immunodeficiency virus 1 (HIV-1) multiplica-
tion depends on a cellular protein, cyclophilin A
(CyPA), that gets integrated into viral particles.
Because CyPA is not required for cell viability, we
attempted to block its synthesis in order to inhibit
HIV-1 replication. For this purpose, we used antisense
U7 small nuclear RNAs (snRNAs) that disturb CyPA
pre-mRNA splicing and short interfering RNAs
(siRNAs) that target CyPA mRNA for degradation.
With dual-specificity U7 snRNAs targeting the 30
and 50 splice sites of CyPA exons 3 or 4, we obtained
an efficient skipping of these exons and a strong
reduction of CyPA protein. Furthermore, short inter-
fering RNAs targeting two segments of the CyPA cod-
ing region strongly reduced CyPA mRNA and protein
levels. Upon lentiviral vector-mediated transduction,
prolonged antisense effects were obtained for both
types of antisense RNAs in the human T-cell line
CEM-SS. These transduced CEM-SS cells showed a
delayed, and for the siRNAs also reduced, HIV-1 multi-
plication. Since the two types of antisense RNAs
function by different mechanisms, combining the
two approaches may result in a synergistic effect.
INTRODUCTION
Despite years of intensive research and some therapeutic suc-
cess, AIDS, caused by infection with human immunodeficiency
virus 1 (HIV-1) continues to be a major health problem world-
wide. New therapeutic or preventive approaches are dearly
wanted, and gene therapy carries considerable promises in
this respect. Many viral or cellular genes are involved in
HIV-1 multiplication and therefore represent potential targets.
Indeed, several strategies attempting to interfere with the pro-
duction or function of such gene products are being tested at
pre-clinical or clinical levels [reviewed in (1–3)].
A host protein that has recently attracted attention as a
potential target for anti-HIV-1 therapy is cyclophilin A
(CyPA). CyPA is a proline cis-trans isomerase that was dis-
covered as the cellular ligand of the immunosuppressive drug
cyclosporin A [csA; (4)]. Disrupting the CyPA gene in both
murine embryonic stem cells and the human Jurkat T-cell line
caused no obvious defects, indicating that CyPA is not essen-
tial for cell survival or that its function can be compensated for
by other factors (5,6). Owing to a specific interaction with the
viral capsid (CA) protein, CyPA gets incorporated into HIV-1
virions and is required for efficient viral replication (7–12).
This interaction can be disrupted by mutating the N-terminal
domain of CA or by treating cells with csA or its non-immuno-
suppressive analog SDZ-NIM 811. If this occurs in infected
cells, the virions produced are of normal morphology and
composition and exhibit normal reverse transcriptase activity,
but they are devoid of CyPA and show a reduced replication
in subsequent target cells. It seems that HIV-1 multiplication is
blocked at some step after viral entry but before reverse tran-
scription starts (12), but CyPA may also be required for viral
entry (13,14). The functional importance of CyPA in HIV-1
multiplication was demonstrated most directly by inactivating
the CyPA gene in Jurkat cells, which resulted in a reduced
ability of these cells to produce viruses (6).
However, the feasibility of down-regulating CyPA to retard
HIV-1 infection has not yet been explored. Here we describe
the use of two different antisense strategies to reduce CyPA
biosynthesis. The first approach consists of skipping internal
CyPA exons by means of modified derivatives of U7 small
nuclear RNA (snRNA). U7 snRNA is the RNA component of
the U7 small nuclear ribonucleoprotein (snRNP) involved in
histone RNA 30 end processing [reviewed in (15)]. We have
demonstrated that, by inserting appropriate antisense
sequences into U7 snRNA, it can be converted from a mediator
of histone RNA processing to an effector of alternative spli-
cing (16–18). Here we show that internal exons of the CyPA
gene can be skipped efficiently by this approach, resulting in
greatly reduced levels of CypA protein. Moreover, HIV-1
multiplication in CEM-SS T-cells that have been stably trans-
duced by lentiviral vectors encoding such antisense U7
snRNAs is significantly impaired.
The other approach used by us to reduce cellular CyPA
levels is RNA interference (RNAi), an evolutionarily con-
served process found in all higher eukaryotes [reviewed in
(19)]. In mammalian cells, RNAi can be induced by 21 nt
RNA duplexes, so-called short interfering RNAs [siRNAs;
(20)]. It is also possible to produce short double-stranded or
hairpin RNAs within the cells, e.g. from RNA polymerase III
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expression vectors. The resulting transcripts can then be pro-
cessed to active siRNAs by the endonuclease dicer (21–24).
Compared with synthetic siRNAs, these DNA vectors hold the
advantage that they can be stably delivered into cells and that a
prolonged inhibition of targeted genes is thereby possible.
Thus, by using hairpin siRNA constructs targeting two
different parts of the CyPA coding region, we obtained an
efficient reduction of CyPA protein, and we succeeded in
transducing these siRNA expression cassettes into CEM-SS
cells using a lentiviral vector. Similar to the work using anti-
sense U7 snRNAs against CyPA, this resulted in an impaired
ability of the cells to sustain HIV-1 replication. Taken
together, these results demonstrate the feasibility of inhibiting
HIV-1 multiplication through a targeted down-regulation of
CyPA. This approach has the potential to become a useful new
tool in the fight against HIV/AIDS.
MATERIALS AND METHODS
Plasmid constructs
U7 snRNA constructs. The sequence complementary to histone
pre-mRNA of plasmid U7 Sm OPT (25) was replaced by
two tandem antisense sequences directed against the 30 and
50 splice sites flanking a particular CyPA exon, respectively
(Figure 1A and B) using a previously described PCR
mutagenesis strategy (17). For insertion into the single ClaI
site upstream of the CMV promoter in the lentiviral vector
pHR’SIN18 (26), the U7 snRNA cassette including promoter
and 30 sequences was amplified with mutagenic primers con-
taining SfuI and ClaI restriction sites and digested by these
enzymes. The insertion orientation was designated as forward
(F) or reverse (R) relative to the orientation of the GFP gene.
LV-glob is a control vector containing the U7/30+50654
snRNA cassette that targets an aberrant exon of the b-globin
gene in certain forms of b-thalassemia (17).
siRNA constructs. Based on the siRNA target finder and design
tool (http://www.ambion.com) and criteria suggested by
Brummelkamp and coworkers (21), antisense sequences tar-
geting nucleotides 276 to 294 (siRNA 276) or 344 to 362
(siRNA 344) of human CyPA mRNA were cloned as double-
stranded DNA oligonucleotides between BglII and HindIII
sites in the pSuper vector (21). The loop sequence was altered
from TTCAAGAGA to TTCATATGA to introduce an NdeI
restriction site (underlined), and this did not reduce the inhi-
bitory activity of the siRNAs (data not shown). The lentiviral
vector pHR’SIN18 (26) was modified by inserting a double-
stranded linker containing SmaI and SalI sites in the ClaI site.
The H1 cassettes carrying the CyPA siRNAs were then
digested with SmaI/SalI and ligated into this pHR’SIN18-
SmaI/SalI vector. A siRNA expression cassette targeting a
Figure 1. CyPA exon skipping induced by transient expression of antisense U7 snRNAs targeting exons 3 or 4. (A) Schematic drawing of modified U7 snRNAs
targeting the 50 and 30 splice sites of exons 3 and 4 of CyPA pre-mRNA. The proteins forming the snRNP particle are depicted as a grey sphere. The resulting splicing
patterns of CyPA mRNA are also indicated. (B) Sequences of antisense U7/E3 and U7/E4 snRNAs used to induce the skipping of CyPA exons 3 and 4, respectively.
The antisense sequences targeting the 30 and 50 splice sites (ss) are shown in bold and underlined. The Sm OPT sequence is in italic. The 30 terminal hairpin of the U7
snRNAs is not shown. (C) RT–PCR analysis of CyPA mRNA splicing in transiently transfected HeLa cells. Lane: 1, mock-transfected HeLa cells; lane 2, cells
transfected with pBlueScript; lane 3, cells transfected with U7 Sm OPT, i.e. the precursor of the two anti CyPA plasmids that encodes a U7 snRNA derivative
complementary to histone pre-mRNA, but which is unable to activate histone RNA 30 end processing (25); lanes 4 and 5, cells transfected with U7/E3 and U7/E4,
respectively; M, size marker (HpaII-digested, end-labelled pBR322). The sizes of PCR bands representing full length and exon-skipped mRNAs are indicated on the
right.
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TCRb minigene mRNA (M. B€uhler, F. Mohn and
O. M€uhlemann, submitted for publication) was cloned into
pHR’SIN18-SmaI/SalI by the same strategy.
All clones were verified by DNA sequencing. Details of the
constructs are available on request.
Cell culture, transfection and lentiviral vector
transduction
293T and HeLa cells were grown in Dulbecco MEM medium
supplemented with 10% fetal calf serum, 100 U/ml penicillin,
100 mg/ml streptomycin at 37C in an incubator containing
5% CO2. The human T-cell lines Jurkat and CEM-SS were
propagated in RPMI 1640 medium containing 10% fetal calf
serum and antibiotics as above. For transient transfection,
2.5 · 105 HeLa cells/well were seeded in a 6-well plate.
Transfection using LipofectAmine (Invitrogen) was then
carried out as described (17).
For lentiviral vector production, 6 · 106 to 6.5 · 106 293T
cells were seeded in 100 mm culture dishes. After 8–16 h, 5 mg
of pVSV-G, 10 mg of the packaging plasmid D8.91 and 15 mg
of transfer vector were co-transfected by the calcium phos-
phate method (27). Media were changed after 12 h. Viral
supernatants (10 ml) were harvested 60 h post-transfection,
filtered through a 0.45 mm filter and concentrated by centri-
fugation at 25 000 r.p.m., 4C for 90 min (Kontron TGA-65
ultracentrifuge, TST 28 rotor). Viral pellets were resuspended
in 1 ml fresh RPMI 1640 for transduction.
For transduction, 1 · 105 HeLa cells or 5 · 105 Jurkat or
CEM-SS cells were seeded per well of a 6-well plate and
infected after 24 h. HeLa cells were incubated with 1 ml of
unconcentrated virus containing 4 mg/ml polybrene. Jurkat and
CEM-SS cells were centrifuged and resuspended in 1 ml con-
centrated virus containing 4 mg/ml polybrene, the suspension
was centrifuged at 1500 g (Kontron TGA-6 centrifuge), 4C
for 2.5 h. Transduced cells were maintained in growth medium
for 7–10 days before FACS sorting.
RNA analyses
Total cell RNA was isolated using Tri-Reagent kits (MRC,
Cincinnati, OH). To detect CyPA mRNA, 250 ng total RNA
was analysed by RT–PCR using rTth DNA polymerase
(Applied Biosystems) for 31 cycles (94C/60C, 1 min
each) with forward and reverse primers corresponding to
sequences in exon 1 (CACCGTGTTCTTCGACATTG) and
5 (CCATGGCCTCCACAATATTC), respectively. The RT–
PCR products were analysed on 6% non-denaturing polyacry-
lamide gels. RNase protection analysis of U7 snRNA was
performed as described in (17). Dried gels were exposed to
phosphor storage screens (Molecular Dynamics) and analysed
with the AIDA program (version 2.31, Raytest Isotopenmess-
gera¨te GmbH, Straubenhardt, Germany).
Western blotting
Cells were lysed in SDS sample buffer and the lysates sepa-
rated by 12% SDS–PAGE and transferred to nitrocellulose
membranes overnight. Polyclonal rabbit anti-human CyPA
(a gift of Dr U. Vonschwedler, University of Utah) or anti-
actin (Sigma) were used as the first antibodies, anti-rabbit
horseradish peroxidase-linked antibody (Promega) as the
secondary antibody. Signals were detected by ECL
chemiluminescence (Amersham Pharmacia) and exposure to
AGFA X-ray film.
HIV-1 replication assay
3 · 104 CEM-SS cells/well were seeded in 24-well plates and
infected with culture supernatant from HUT cells constitu-
tively producing virions of the HIV-1 strain NL4-3. At various
times post-infection, 50 ml supernatant samples were harvested
and stored at 20C until analysed. Virus was lysed by addi-
tion of 1/10 volume of 5% Triton X-100; 5 ml aliquots thereof
were transferred directly into a complete RT–PCR master mix
(ABI-Applera), supplemented with primers and VIC-labeled
ENV probe (V. Brondani and T. Klimkait, manuscript in
preparation), and quantitatively assessed for the presence of
HIV-specific RNA. The RT step was performed at 47C for
30 min, followed by a hot start enzyme activation for 10 min
at 95C, and 45 amplification cycles (30 s at 95C/1 min
at 57C). All results are plotted as real-time PCR-determined
RNA copies per millilitre using a characterized pNL4-3 virus
stock as a quantitation standard.
RESULTS
Antisense U7 snRNA-mediated skipping of CyPA
exons 3 and 4
We have developed a method, based on antisense U7 snRNAs,
to promote the exclusion of internal exons from a pre-mRNA
(16–18). Especially double-target U7 snRNAs, i.e. RNAs car-
rying two tandem sequences complementary to sites upstream
and downstream of the targeted exon, respectively, very effi-
ciently induce exon skipping (17). Presumably, these RNAs
bind both targets simultaneously thereby forming a looped
structure that compromises the exon’s recognition by the
splicing machinery.
Here, we tried to reduce the expression of the HIV-1 host
factor CyPA by this approach. The CyPA gene has 5 exons,
and we designed U7 double-target constructs carrying anti-
sense sequences against the 30 and 50 splice sites flanking
exons 3 or 4 (Figure 1A and B). Because eliminating either
of these exons (or both in combination) will disturb the CyPA
reading frame, we expected the severely truncated protein to
be unable to interact with CA, and perhaps even to be unstable.
Moreover, the mRNA might have been subject to nonsense-
mediated decay.
Initially, these U7 constructs were transiently transfected
into HeLa cells, and total RNA was analysed for the presence
of exons 3 and 4 by RT–PCR. With RNA from mock-trans-
fected cells or from cells transfected with two different control
plasmids, a 416 bp RT–PCR product corresponding to cor-
rectly spliced, full-length CyPA mRNA was obtained (Figure
1C, lanes 1 to 3). In contrast, transfection of the U7/E3 con-
struct yielded an additional product of 326 bp (lane 4) that
corresponded to mRNA lacking exon 3, as was confirmed by
DNA sequencing. Moreover, transfection of the U7/E4 con-
struct induced a very efficient exon skipping judging from the
low remaining amount of full-length CyPA mRNA (lane 5).
Interestingly, besides the expected 243 bp exon 4-skipped
RT–PCR band, another product of 154 bp was also detected.
Sequencing revealed that it reflected the simultaneous
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skipping of exons 3 and 4. A low level of double exon skipping
was also observed with the U7/E3 construct (lane 4).
To analyse the effects of these U7 constructs on CyPA pre-
mRNA splicing in T-cells in a persistent state, we used a
lentiviral vector for stable cell transduction. The U7/E3 and
U7/E4 cassettes were cloned into the vector pHR’SIN18 (26)
in both the forward (F) and reverse (R) orientation (Figure
2A). The resulting plasmids were designated as LV-E3F, LV-
E3R, etc. Unfortunately, no transduction was obtained with the
LV-E4R vector. Although this phenomenon was not analysed
in full detail, it seems to have been due to some defect in the
production of viral vector genomic RNA (data not shown).
In CEM-SS T-cells stably transduced with the other three
viruses, the levels of antisense U7 snRNAs were measured by
an RNase protection assay (17,25). The structure of the probe
and the protected products corresponding to endogenous
human U7 snRNA and to the antisense U7 snRNA transcribed
from the integrated lentiviral vectors are shown schematically
in Figure 2B. This analysis revealed that the cells contained 2
to 3 times more of the introduced U7 snRNAs than endogen-
ous human U7 snRNA (Figure 2C). Moreover an RT–PCR
analysis of CyPA mRNA showed that the skipping of both
exons 3 and 4 was enhanced compared with the results
obtained in transiently transfected HeLa cells. More than
90% of CyPA pre-mRNAs were skipped with the two types
of exon 3-targeting viruses (Figure 2D, lanes 4 and 5), and full-
length CyPA mRNA was almost undetectable in cells trans-
duced by LV-E4F (lane 6). In contrast, control cells transduced
by the empty pHR’SIN18 vector (LV; lane 2) or by LV-glob
(17), carrying an unrelated double-target U7 snRNA cassette
Figure 2. CyPA exon skipping and reduced CyPA protein synthesis in stably transduced CEM-SS T-cells. (A) Insertion of antisense U7 snRNA cassettes into the
pHR’SIN18 lentiviral vector (26). The two orientations of U7 gene inserts are designated as ‘F’ (forward) and ‘R’ (reverse), relative to GFP transcription. (B)
Structure of riboprobe used for RNase protection assay in (C) and of the resulting protected bands. A 280 nt riboprobe was obtained by run-off transcription with SP6
RNA polymerase to the StuI site of U7 Sm OPT (17,25). Antisense (as) U7 snRNAs expressed from the stably transduced cells are complementary to this probe over
40 nt including the Sm OPT sequence and the 30 terminal hairpin; endogenous human (h) U7 snRNA differs in the Sm binding site and the 30 hairpin leaving a
protected fragment of24 nt that can be used to monitor total RNA recovery. (C) RNase protection assay of total RNAs from stably transduced CEM-SS cells. Note
that the lane order is different from that used in panels (D) and (E). (D) RT–PCR analysis of CyPA mRNA splicing in stably transduced cells. (E) Analysis of CyPA
protein by western blotting probed with polyclonal anti-CyPA antibody. Polyclonal anti-actin antibody was used as loading control. Lane: 1, untransduced cells
(Mock); lanes 2 and 3, cells transduced by empty pHR’SIN18 vector (LV) and by LV-glob (17) encoding a double-target U7 snRNA that targets aberrant splice sites in
b-globin pre-mRNA caused by the IVS2-654 b-thalassemic mutation; lanes 4 and 5, cells transduced by LV-E3F and LV-E3R; lane 6, cells transduced by LV-E4F.
Relevant bands are indicated on the left of each panel.
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from a b-thalassemia system (lane 3), did not yield any
skipped products, indicating that the effects of these antisense
U7 snRNAs were sequence specific. Finally, CyPA protein
levels were assayed by western blotting with anti-CyPA anti-
body. Compared to a b-actin control, the level of CyPA protein
was significantly reduced in the three cell lines displaying
efficient exon skipping due to the antisense U7 snRNAs (Fig-
ure 2E). Very similar results were also obtained in HeLa and
Jurkat cells transduced with the LV-E3F, LV-E3R, LV-E4F
vectors (data not shown).
Inhibition of CyPA expression by siRNAs
As a second approach to reduce the levels of CyPA mRNA and
protein and thus to affect the cells’ ability to sustain HIV-1
multiplication, we used an existing system for the production
of hairpin RNAs that can be processed into siRNAs in mam-
malian cells (21). Based on established criteria (see Materials
and Methods), two sequences corresponding to nucleotides
265 to 283 and 330 to 348 of CyPA mRNA, respectively,
were chosen as potential targets (Figure 3A).
In transient transfections of HeLa cells, both of these
siRNAs strongly reduced CyPA protein levels as indicated
by western blot (Figure 3B). However, to achieve a prolonged
inhibition, long-term and stable expression of siRNA is
required. Similar to the strategy used for delivering U7
snRNA constructs, the two CyPA siRNA constructs were
therefore introduced into the same lentiviral vector, upstream
of the CMV promoter driving the GFP gene. However,
because a directional cloning strategy was chosen, they
were systematically inserted in the reverse orientation relative
to the GFP gene (Figure 3C).
HeLa and CEM-SS cells were then transduced with the
resulting LV-siRNA vectors and the cells were sorted based
on GFP expression. Western Blots revealed that CyPA was
almost completely eliminated by the expression of anti-CyPA
siRNAs in both HeLa (data not shown) and CEM-SS cells
(Figure 3E). In agreement with this, a semi-quantitative
Figure 3. siRNA-mediated inhibition of CyPA expression. (A) Schematic diagram of the pSuper plasmid for expression of hairpin siRNAs (21). A hairpin siRNA
precursor is expressed under the control of the human H1 promoter. The sequences of the siRNA targets in CyPA and TCRb mRNAs are indicated below. For the
CyPA targets, the positions from the start of the mRNA are also indicated. (B) Western blot analysis of CyPA protein in transiently transfected HeLa cells carried out
as in Figure 2E. Lane: 1, mock-transfected cells; lane 2, cells transfected by pSuper vector; lanes 3 and 4, cells expressing anti-CyPA siRNA 265 and siRNA 330,
respectively. (C) Schematic representation of the lentiviral vectors expressing various siRNAs. The H1-siRNA cassettes were inserted into a modified pHR’SIN18
lentiviral vector [(26); see Materials and Methods], upstream of the CMV–GFP selection marker, but in the reverse orientation respective to the GFP gene. (D) RT–
PCR analysis of CyPA mRNA in stably transduced CEM-SS cells. The analysis was performed as in Figure 2D, except that the amplification was reduced to 25 cycles
so that the signals reflect mRNA abundance semi-quantitatively (37). Only the band corresponding to full-length CyPA mRNA is shown. Lane: 1, untreated cells; lane
2, cells transduced by the empty pHR’SIN18 lentiviral vector; lane 3, cells transduced by pHR’SIN18 containing the empty pSuper expression cassette; lanes 4 to 6,
cells stably transduced by pHR’SIN18-derived vectors encoding the indicated siRNAs. (E) Western blot analysis of CyPA protein in stably transduced CEM-SS cells.
Lane numbers and cell samples correspond to those used in (D).
3756 Nucleic Acids Research, 2004, Vol. 32, No. 12
RT–PCR analysis showed a strong reduction in CyPA mRNA
in CEM-SS cells expressing anti-CyPA siRNA 265 or siRNA
330 (Figure 3D, lanes 5 and 6, respectively). In contrast, no
mRNA reduction was observed in cells transduced by lenti-
viral vectors containing either no siRNA cassette (LV; lane 2),
an empty pSuper cassette (lane 3), or a cassette that encodes an
siRNA targeting a TCRb minigene (lane 4). Importantly, since
the genes encoding the anti-CyPA siRNAs have been inte-
grated into the genome of the targeted cells, elimination of
CyPA expression will be maintained for a prolonged time,
resulting in CyPA-deficient cell lines.
Delayed HIV-1 replication in CEM-SS T-cells showing
reduced CyPA protein levels
Finally, we analysed whether HIV-1 replication was affected
in the CEM-SS cells that showed reduced CyPA protein levels
due to the expression of antisense U7 snRNAs or siRNAs. For
this purpose, the replication of the HIV-1 clone pNL4-3 was
followed in the stably transduced CEM-SS cells over a period
of 14 days. HIV-1 multiplication in untreated CEM-SS cells
initiated between days 4 to 7 post-infection, depending on the
multiplicity of infection used, and peaked around day 10 (Fig-
ure 4, filled circles). Very similar multiplication kinetics were
observed in CEM-SS cells transduced with the pHR’SIN18-
derived vector encoding TCRb-specific siRNA (Figure 4A and
B, filled triangles). Most importantly, however, the two cell
lines expressing siRNAs 265 (empty circles) and 330 (empty
triangles) showed a strongly reduced viral multiplication, at
both the lower (Figure 4A) and the higher (Figure 4B) multi-
plicity of infection. This reduction correlated with a delayed
and much reduced appearance of virus-induced cell fusion
events.
HIV-1 multiplication was also analysed in the CEM-SS
cells transduced with the U7-containing lentiviral vectors.
HIV-1 multiplication was slightly reduced in CEM-SS cells
transduced with LV-glob encoding a double-target U7 snRNA
that targets b-globin pre-mRNA (Figure 4C and D, filled
squares). However, all three CyPA-specific vectors, LV-
E3F (empty squares), LV-E4F (empty diamonds) as well as
LV-E3R (data not shown), caused a more strongly delayed and
reduced replication of HIV-1. In keeping with the somewhat
higher residual CyPA levels detected by western blotting (see
above), the effect on viral multiplication was less pronounced
for these antisense U7 snRNAs than for the siRNAs targeting
CyPA. Moreover, when the cells were infected at the higher
multiplicity, the cumulative virus production eventually
reached a similar level as seen for the cells transduced with
LV-glob (Figure 4D). In summary, however, both strategies
used here were effective in inhibiting HIV-1 multiplication.
DISCUSSION
In this paper, we have described the successful application of
two different molecular strategies, U7 snRNA-mediated mod-
ulation of splicing and RNAi, to reduce CyPA, a cellular
protein that is important for HIV-1 replication. Through the
use of lentiviral vectors, a prolonged reduction of CyPA could
be obtained in a T-cell line, and, as a result, the ability of the
cells to sustain HIV-1 multiplication was strongly reduced or
at least delayed.
Because classical immunological approaches to combat
HIV-1, due to inherent biological properties of the virus,
are difficult to apply, alternative strategies, termed ‘intracel-
lular immunization’ (28) bear greater promises. This term does
not imply that the immune system should be introduced into
cells, but rather that the cells’ molecular make-up is modified
in order to render them resistant to infection by HIV-1 or
unable to sustain viral multiplication. Along these lines, a
variety of strategies have been tested, mostly with the aim
to interfere with the production or function of viral sequences
or proteins. Only recently, with a more detailed dissection of
the HIV-1 life cycle, certain cellular factors important for viral
replication have also come into view as potential therapeutic
or preventive targets [reviewed in (3)]. So far, however, the
Figure 4. Reduced replication of wild-type HIV-1 in CEM-SS cells showing a
permanent inhibition of CyPA expression. CEM-SS cells were infected with the
HIV-1 clone pNL4-3 at multiplicities of 0.5 (A and C) or 1.7 (B and D) copies
per cell. The number of viral genomes in culture supernatants was determined by
quantitative RT–PCR analysis at days 4, 7, 11 and 14 post-infection, and
cumulative values are shown. (A and B) Effects of siRNAs 265 (empty
circles) and 330 (empty triangles). (C and D) Effects of U7 snRNAs
targeting CyPA exons 3 (empty squares) and 4 (empty diamonds). As
controls, the replication in untreated CEM-SS cells (filled circles) or cells
transduced by pHR’SIN18 lentiviral vectors encoding either TCRb-specific
siRNA (filled triangles) or a double-target U7 snRNA that targets b-globin
pre-mRNA (filled squares) are shown. All experimental values represent
well correlating averages of independent duplicate experiments.
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practicability of such an approach has only been explored for
few of these host factors.
In our work, we selected CyPA as the target, because this
protein had been shown to play multiple roles in the early
stages of HIV-1 replication (see Introduction). Moreover, sev-
eral lines of evidence had shown that the protein is neither
crucial for early development nor for cell viability (5,6). In a
therapeutic setting, this is an important point to consider in
order to minimize side effects caused by the treatment. This is
of particular concern because this therapeutic approach, for
being long-lasting, should not be targeted directly to T-cells,
but rather to hematopoietic stem cells. Thus, CyPA would be
reduced in all hematopoietic stem cell-derived lineages. In this
respect, it is important to mention that down-regulating CyPA,
unlike the application of csA, is not likely to cause immuno-
suppression, because the immunosuppressive activity of csA is
not due to an interference with CyPA function but rather
involves an interaction of the CyPA/csA complex with calci-
neurin, resulting in its inactivation (29,30). The balance, in a
therapeutic situation, between any possible side effects and the
benefit of having T-helper cells that are resistant to HIV-1
replication remains to be determined.
In previous work, antisense U7 snRNAs were used to affect
pre-mRNA splicing to correct defective transcripts of genes
affected by genetic disorders, such as b-thalassemia (16,17) or
muscular dystrophy (18). In the present study, the aim was to
interfere with CyPA splicing, and hence CyPA protein syn-
thesis, to an extent sufficient to inhibit HIV-1 multiplication.
This meant that a high efficiency of exon skipping had to be
achieved. In general the amounts of full-length, correctly
spliced mRNA and those of residual CyPA protein correlated
well with each other, and, even in HeLa cells transiently
transfected with the U7 constructs, the targeted exon was
skipped in a significant fraction of CyPA mRNA (Figure
1). This fraction of mRNA displaying exon skipping was
even higher in stably transduced CEM-SS cells (Figure 2)
to the extent that full-length CyPA mRNA was sometimes
virtually absent. This could either have been due to the fact
that all cells expressed the antisense U7 snRNAs or to a more
favorable ratio of U7 snRNA to CyPA pre-mRNA within the
stably transduced cells. It has been shown previously that the
CyPA concentration can vary among different cell lines
(31,32). Moreover, in our experience, U7 snRNA expression
in stably transduced cell lines is always quite high, reaching
levels that are often higher than those of endogenous U7
snRNA (see Figure 2C for example).
Interestingly, with both U7 constructs, and in particular
with the one targeting exon 4, a certain amount of combined
skipping of exons 3 and 4 was observed. The skipping of the
second non-targeted exon was most likely not due to a lack of
specificity, because the splice sites flanking exons 3 and 4
differ as much or more from each other as those of other
CyPA exons or exons from other genes which were unaf-
fected by the treatment. A similar skipping of multiple exons
was previously observed when antisense oligonucleotides
(33) or U7 snRNAs (18) were used to induce the skipping
of internal exons in dystrophin mRNA. This implies that
certain groups of exons may be recognized by the splicing
machinery in a concerted fashion so that they tend to be
coordinately included in or excluded from the mRNA. How-
ever, the mechanism for this is unknown. In the case of the
CyPA exons 3 and 4 targeted in this work, this phenomenon
does not compromise an inhibition of HIV-1 replication,
because skipping both exons has the same effect as skipping
only exon 3, i.e. only a severely truncated protein consisting
of exons 1 and 2 could be synthesized. It should be noted,
however, that we have never observed such truncated pro-
teins (data not shown), indicating that they may be subject to
rapid degradation within the cells.
In addition to the U7 snRNA-based approach, we showed
that CyPA gene expression can also be efficiently and perma-
nently silenced using a DNA vector-based RNAi approach
(Figure 3). The somewhat surprising fact that the hairpin
siRNA expression cassette could be introduced into a lentiviral
vector without strongly impairing the production of recombi-
nant virions, greatly adds to the versatility of the RNAi system
by providing it access to many cell types which are not amen-
able to DNA transfection by standard protocols. It is in line
with the reports of others who have recently demonstrated the
suitability of lentiviral vectors for stably introducing siRNA
expression cassettes into cells [e.g. (34,35)].
Importantly, both types of antisense RNA strategies not
only led to a down-regulation of CyPA levels, but also
affected the cells’ ability to support HIV-1 multiplication.
However, the observed reduction and delay in replication
was greater for the siRNAs than for the antisense U7
snRNAs, which is consistent with the fact that the reduction
in CyPA protein obtained by the RNAi approach was some-
what stronger than that obtained by U7 snRNA-mediated
exon skipping.
Interestingly, with even higher multiplicities of infection
(>5 viral copies/cell) both types of antisense RNAs, did
not completely abolish, but only delayed, HIV-1 multiplica-
tion (data not shown). This phenomenon is already apparent
for the snRNAs at the higher multiplicity of infection shown
(1.7 copies/cell; Figure 4D). A similar resumption of viral
replication after an initial suppression was previously
observed in Jurkat cells whose CyPA gene had been inacti-
vated by targeted homologous recombination (6). The authors
of that study demonstrated that the resumed viral replication
was not due to the emergence of viral escape mutants. A
possible explanation for this phenomenon is that the accumu-
lation of a factor above some threshold concentration may
overcome the block caused by the unavailability of CyPA.
This could be related to a recently described role of CyPA
in modulating HIV-1’s response to host restriction factors for
retro- and lentiviruses. Apparently, preventing the interaction
between CyPA and viral capsid protein exposes the virus to the
action of the human restriction factor Ref-1 (36). Since this
factor is limiting, the observed delay in viral multiplication
could reflect the time needed for the synthesis of sufficient
capsid protein to titrate out Ref-1.
In summary, our experiments establish CyPA as a potential
target for an anti-HIV therapeutic approach. Moreover, they
demonstrate for the first time that U7 snRNA-mediated mod-
ification of pre-mRNA splicing can be applied to the inhibition
of HIV-1 multiplication. Potentially, the siRNA and U7
snRNA approaches can be combined in a single transduction
vector to obtain stronger and more lasting effects. Such an
inhibition of CyPA function may provide an alternative or a
complement to other HIV-1 gene therapies that already exist or
are being developed.
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